Taribavirin 是一种肌苷一磷酸脱氢酶抑制剂，具有抗多种病毒的活性，特别是丙型肝炎病毒和流感病毒。Taribavirin 是一种利巴韦林前药，旨在集中在肝脏内以靶向 HCV 感染的肝细胞，同时最小化红细胞 (RBC) 内的分布和溶血性贫血的发展。
Taribavirin is an inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus[1].Taribavirin, is a ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia[2].
Taribavirin (0-2 μM; 24 hours) significantly induces MCF-7 cell death, recording half inhibitory effect (IC50) of 0.756 μM in MCF-7 cells[1]. Cell Viability Assay[1] Cell Line: MCF-7 cells
[1]. Abd-Rabou AA, et al. Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer. Pharm Res. 2018 Feb 27;35(4):76. [2]. Deming P, et al. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011 Oct;20(10):1435-43.
动态评分
0.0